Cargando…

Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin

This study examines the relationship between glycated haemoglobin (A1C) levels and treatment persistence with, or time to discontinuation of, basal insulin in patients with type 2 diabetes (T2D) newly initiating insulin. Claims data were extracted from the Optum Clinformatics database from January 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Fang Liz, Xie, Lin, Pan, Chunshen, Wang, Yuexi, Vaidya, Neel, Ye, Fen, Preblick, Ronald, Meneghini, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947595/ https://www.ncbi.nlm.nih.gov/pubmed/29278460 http://dx.doi.org/10.1111/dom.13200

Ejemplares similares

Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
por: Zhou, Fang L., et al.
Publicado: (2019)

Association of hypoglycaemia severity with clinical, patient‐reported and economic outcomes in US patients with type 2 diabetes using basal insulin
por: Meneghini, Luigi F., et al.
Publicado: (2018)

Impact of delaying treatment intensification with a glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database
por: Tong, Liyue, et al.
Publicado: (2017)

Real‐world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin
por: Zhou, Fang Liz, et al.
Publicado: (2018)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
por: Blonde, Lawrence, et al.
Publicado: (2018)

More patients reach glycaemic control with a fixed‐ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time‐to‐control analysis of LixiLan‐O and LixiLan‐L
por: Frias, Juan, et al.
Publicado: (2018)

Clinical outcomes in real‐world patients with type 2 diabetes switching from first‐ to second‐generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study
por: Sullivan, Sean D., et al.
Publicado: (2018)

Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population
por: Lee, Seina, et al.
Publicado: (2018)

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
por: Mauricio, Dídac, et al.
Publicado: (2017)

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs
por: Wei, Wenhui, et al.
Publicado: (2014)

Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
por: Pettus, Jeremy, et al.
Publicado: (2019)

Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes
por: Zhou, Fang Liz, et al.
Publicado: (2018)

The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real‐world setting
por: Meneghini, Luigi F., et al.
Publicado: (2019)

Efficacy of two telemonitoring systems to improve glycaemic control during basal insulin initiation in patients with type 2 diabetes: The TeleDiab‐2 randomized controlled trial
por: Franc, Sylvia, et al.
Publicado: (2019)

Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
por: Kalra, Sanjay
Publicado: (2015)

Insulin glargine 300 U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial
por: Meneghini, Luigi, et al.
Publicado: (2020)

MITOSIS IN CHLAMYDOMONAS REINHARDTII BASAL BODIES AND THE MITOTIC APPARATUS
por: Coss, Ronald A.
Publicado: (1974)

Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care
por: Mehta, Roopa, et al.
Publicado: (2021)

Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities
por: Brod, Meryl, et al.
Publicado: (2014)

The importance of the initial period of basal insulin titration in people with diabetes
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey
por: Svensson, Ann-Marie, et al.
Publicado: (2020)

Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
por: Vilsbøll, Tina, et al.
Publicado: (2019)

Early Insulin Treatment in Type 2 Diabetes: What are the pros?
por: Meneghini, Luigi F.
Publicado: (2009)

Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study
por: Goldenberg, Ronald M., et al.
Publicado: (2023)

Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy
por: Patel, Bimal V, et al.
Publicado: (2008)

Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data
por: Peters, Anne, et al.
Publicado: (2020)

Transcriptome analysis of basal and luminal tumor-initiating cells in ErbB2-driven breast cancer
por: Borcherding, Nicholas, et al.
Publicado: (2015)

A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the ACHIEVE Control study
por: Meneghini, Luigi F., et al.
Publicado: (2020)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials
por: Freemantle, N, et al.
Publicado: (2013)

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
por: Meneghini, L., et al.
Publicado: (2019)

Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes
por: Roussel, Ronan, et al.
Publicado: (2020)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Initiating insulin therapy in children and adolescents with type 1 diabetes mellitus
por: Wangnoo, Subhash Kumar
Publicado: (2015)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Relationship of the Magnitude of Member Cost-Share and Medication Persistence With Newly Initiated Renin Angiotensin System Blockers
por: Zhang, Dongmu, et al.
Publicado: (2007)

Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real‐world results from the DELIVER Naïve cohort study
por: Bailey, Timothy S., et al.
Publicado: (2019)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hflfirgevochenvslg27ticglq